Literature DB >> 28384462

Can a 10-Minute Questionnaire Identify Significant Psychological Issues in Patients With Temporomandibular Joint Disease?

Shang-Lun Lin1, Shang-Liang Wu2, Hsien-Te Huang3, For-Wey Lung4, Tzong-Cherng Chi5, Jung-Wu Yang6.   

Abstract

PURPOSES: For patients with disc displacement disorders (DDDs), psychiatric illness increases the risk of worsening postsurgical pain, postoperative delirium, postoperative incomplete recovery, and worse postoperative life quality. This study provides a fast and practical protocol to evaluate psychological conditions of patients with DDDs of the temporomandibular joint (TMJ) in clinical care.
MATERIALS AND METHODS: The populations under investigation in this cross-sectional study included patients with DDD who received treatment from October 2012 through June 2016. Variables included age, gender, education level, and TMJ (Axis I) and psychological (Axis II) evaluations. The 13-item protocol of Axis II evaluations contained a 5-item Brief Symptom Rating Scale (BSRS-5), a pain visual analog scale (VAS; 1 item), major life events (3 items), suicidal risk (3 items), and substance use (1 item). Analysis of variance, χ2 test, and multivariate logistic regression were used for analyses.
RESULTS: Of 177 patients, 75.14% were women (mean age, 37.46 ± 14.06 yr). Pain VAS scores clearly supported the following ranking of psychosocial discomforts: disc displacement without reduction with limited opening (DDWORWLO) > disc displacement without reduction without limited opening > disc displacement with reduction. Pain VAS and BSRS-5 correlated with 5 variables in Axis I (trismus, acute TMJ pain, chronic awake bruxism, chronic sleep bruxism, and deep bite). The DDD study indicated that 9.6% of patients required urgent referrals to mental health resources (MHRs) for their moderate and high suicidal risk DDD and 77% required nonurgent referrals to MHRs for their psychiatric morbidity.
CONCLUSIONS: This study found that patients with DDD showed a prevalence of suicidal ideation and mean BSRS scores that were higher for anxiety, hostility, depression, interpersonal hypersensitivity, and insomnia than in the general population. Patients with trismus or acute TMJ pain could have a higher pain VAS score; chronic awake bruxism could involve greater hostility and lower depression; chronic sleep bruxism could increase sensitivity to interpersonal interactions; and deep bite could involve a higher anxiety level. DDWORWLO produced the highest pain VAS score in patients with DDD. The 13-item Axis II evaluations can offer useful clues for oral and maxillofacial surgeons and other specialists to collaborate with MHRs.
Copyright © 2017 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28384462     DOI: 10.1016/j.joms.2017.02.024

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  3 in total

1.  A Cross-Sectional Survey on the Association between Dental Health Conditions and University Personality Inventory Scores among University Students: A Single-Center Study in Japan.

Authors:  Shigeo Ishikawa; Naohiko Makino; Hitoshi Togashi; Nanami Ito; Atsushi Tsuya; Makiko Hayasaka; Tsuneo Konta; Naoki Okuyama; Kazuyuki Yusa; Mitsuyoshi Iino
Journal:  Int J Environ Res Public Health       Date:  2022-04-12       Impact factor: 4.614

2.  The Impact of Wearing a Face Mask during the COVID-19 Pandemic on Temporomandibular Joint: A Radiological and Questionnaire Assessment.

Authors:  Moath Zuhour; Majid Ismayilzade; Mehmet Dadacı; Bilsev Ince
Journal:  Indian J Plast Surg       Date:  2022-02-25

3.  Temporomandibular disorders in patients with polysomnographic diagnosis of sleep bruxism: a case-control study.

Authors:  Andrea Sinclair; Mieszko Wieckiewicz; Dominik Ettlin; Raimundo Junior; Antônio Sérgio Guimarães; Michele Gomes; Miguel Meira E Cruz
Journal:  Sleep Breath       Date:  2021-08-08       Impact factor: 2.816

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.